News
-
VistaGen Therapeutics has announced that it signed a deal giving EverInsight Therapeutics development and commercialization rights to Vistagen’s PH94B aloradine nasal spray for anxiety disorders in China, South Korea, and a number of other Asian countries.… Read more . . .
-
Gilead Sciences Chairman and CEO Daniel O’Day has announced that the company has received FDA approval for a Phase 1 trial of inhaled remdesivir and will initiate the study within a week. Trials of the… Read more . . .
-
Vaccine developer Intravacc has published data from a preclinical study of an intranasal whooping cough vaccine demonstrating strong immune responses in mice. The intranasal vaccine also prevented colonization of the lung, trachea, and nose by… Read more . . .
-
Inhalation Sciences (ISAB) has announced that a “noted global pharma company” has placed an order worth €75,000 for a contract research project utilizing ISAB’s DissolvIt system. The DissolvIt module is used to simulate dissolution and… Read more . . .
-
The FDA has approved Evoke Pharma’s Gimoti metoclopramide nasal spray for the treatment of diabetic gastroparesis, the company said. Evoke originally submitted an NDA for Gimoti in in June 2018 and acknowledged receipt of a complete response… Read more . . .
-
DPI developer TFF Pharmaceuticals said that the FDA has granted orphan drug designation to its dry powder tacrolimus for the prevention of lung transplant rejection. The company also said that it plans to initiate a… Read more . . .
-
North Carolina-based Renovion said that it has raised $8.1 million in a Series A financing round for development of its ARINA-1 nebulized glutathione/bicarbonate/ascorbic acid formulation for the treatment of chronic lung diseases. ARINA-1, which is… Read more . . .
-
Tonix Pharmaceuticals has announced that it will acquire assets from Trigemina, Inc that include intranasal oxytocin for the treatment of migraine headaches. Trigemina had licensed the nasal spray, now called TNX-1900, from Stanford University, and… Read more . . .
-
Impel NeuroPharma has announced that the Phase 3 STOP 301 study of INP104 intranasal dihydroergotamine mesylate (DHE) for the treatment of acute migraine met its primary objectives, with 66.3% of patients experiencing pain relief and… Read more . . .
-
Inhalation CDMO Vectura and inhaled drug developer Aerami Therapeutics (formerly Dance Biopharm) have signed an agreement for development of inhaled imatinib for the treatment of pulmonary arterial hypertension (PAH), the companies said. Aerami will pay nothing… Read more . . .
Upcoming Events
Sponsored by Intertek
Want information about upcoming OINDP-related events delivered directly to your inbox? click here
No events are found.